Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy Read more →

BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts Read more →

BioMarin axes $270M rare disease asset after missing phase 3 endpoint Read more →